Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Electronic Resource  (2)
  • 1985-1989  (2)
  • 1965-1969
  • CA 15-3  (1)
  • Mammacarcinom  (1)
  • 1
    Electronic Resource
    Electronic Resource
    Springer
    Journal of molecular medicine 67 (1989), S. 813-817 
    ISSN: 1432-1440
    Keywords: Tumor marker ; MCA ; CA 15-3 ; Breast cancer
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Mucin-like cancer-associated antigen (MCA), a new tumor marker using the mouse monoclonal antibody b-12 is thought to be of value in the management of patients with breast cancer. In this study sera from 191 female patients with breast cancer (112 with progressive disease [PD] and 79 with no evidence of disease [NED]) were analyzed for MCA levels and compared with those of cancer antigen 15-3 (CA 15-3) in single determination and in combination with carcinoembryonic antigen (CEA) and tissue polypeptide antigen (TPA). A cut-off level of 14 U/ml for MCA seems to be more appropriate than the recommended 11 U/ml to distinguish between PD and NED in patients with breast cancer. Although there was a fairly good correlation of MCA to CA 15-3, MCA was inferior in sensitivity and specificity to CA 15-3. Patients with osseous metastases and those with more than one metastatic site showed higher MCA levels than patients with visceral or soft tissue metastases, a fact which was comparable to CA 15-3. Combining MCA and CA 15-3 resulted in a gain in specificity but marked loss of sensitivity. The combination of MCA and CEA results also in a loss of sensitivity whereas the combination of CA 15-3 and CEA showed an increased specificity and only a negligible loss of sensitivity. The combination of MCA with TPA is of little value in the follow-up of breast cancer, as is the combination of CA 15-3 with TPA. The combination of CA 15-3 with CEA can be still recommended for follow-up for early detection of metastases in breast cancer. Further investigations with MCA to determine the lead time of this new marker as well as its role as a possible monitor of the response to therapy are recommended.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1435-2451
    Keywords: Breast cancer ; Prospective randomized trial ; Mammacarcinom ; Randomisierte Studie
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Operatives Vorgehen, Resektion (R) versus modifiziert radikale Mastektomie (M) und M versus klassisch radikaler Mastektomie (RM) und Fragen der adjuvanten Therapie, Chemound Chemoimmunotherape gegenüber einer Kontrollgruppe wurden 241 Patientinnen nach rezidivfreiem und absolutem Überleben beurteilt. Die mediane Beobachtungszeit beträgt 48 Monate. R schnitt gegenuber M in beiden Parametern signifikant schlechter ab. Dagegen fand sich kein Unterschied zwischen M and RM. Im Gegensatz zur Auswertung nach 30 min konnte kein signifikanter Unterschied bei den adjuvant behandelten Patientinnen nach 48 Monaten gefunden werden. Patientinnen mit receptor-negativen, Grad III Tumoren überlebten mit Chemotherapie signifikant besser.
    Notes: Summary In 241 patients, with a median observation time of 48 months, surgical treatment, partial resection (R) versus modified radical mastectomy (M) and M versus Halsted's procedure (RM), as well as adjuvant treatment forms, chemotherapy and chemoimmunotherapy versus an untreated control group were all evaluated. Whereas M showed significantly better results (RFS, absolute survival) than R, no difference could be observed when comparing M and RM. At 48 months no significant differences could be detected for patients with adjuvant chemotherapy, but patients bearing receptornegative, grade III tumors did significantly better when receiving chemotherapy.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...